Difference between revisions of "Lisocabtagene maraleucel (Breyanzi)"
Jump to navigation
Jump to search
m |
|||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*2/5/2021: Approved for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]] (including [[Transformed lymphoma|DLBCL arising from indolent lymphoma]]), [[high-grade B-cell lymphoma]], [[Primary mediastinal B-cell lymphoma|primary mediastinal large B-cell lymphoma]], and follicular lymphoma grade 3B. | *2/5/2021: Approved for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]] (including [[Transformed lymphoma|DLBCL arising from indolent lymphoma]]), [[high-grade B-cell lymphoma]], [[Primary mediastinal B-cell lymphoma|primary mediastinal large B-cell lymphoma]], and follicular lymphoma grade 3B. | ||
| + | |||
| + | == Patient Drug Information== | ||
| + | *[https://www.fda.gov/media/145711/download Lisocabtagene maraleucel (Breyanzi) Package Insert]<ref>[https://www.fda.gov/media/145711/download Lisocabtagene maraleucel (Breyanzi) Package Insert]</ref> | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' JCAR017 | *'''Code name:''' JCAR017 | ||
*'''Brand names:''' Breyanzi, Liso-cel | *'''Brand names:''' Breyanzi, Liso-cel | ||
| + | |||
| + | ==References== | ||
[[Category:Chimeric antigen receptor T-cells]] | [[Category:Chimeric antigen receptor T-cells]] | ||
Revision as of 11:38, 4 April 2021
Mechanism of action
From the NCI Drug Dictionary: A preparation of a defined ratio of CD4+ and CD8+ autologous T lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induce selective toxicity in CD19-expressing tumor cells.
Diseases for which it is used
- Diffuse large B-cell lymphoma
- High-grade B-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Transformed lymphoma
History of changes in FDA indication
- 2/5/2021: Approved for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Patient Drug Information
Also known as
- Code name: JCAR017
- Brand names: Breyanzi, Liso-cel